Melanoma CT: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{YD}}; {{SSK}} | {{CMG}} {{AE}} {{YD}}; {{SSK}} | ||
==Overview== | ==Overview== | ||
Melanoma can appear as a soft tissue mass on CT scan. Chest CT scan is recommended for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years). | Melanoma can appear as a [[soft tissue]] [[mass]] on [[Computed tomography|CT scan]]. [[Chest]] [[Computed tomography|CT scan]] is recommended for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in [[Patient|patients]] who have been [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IA-IV melanoma and for [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|Stage]] IIB-IV melanoma (annually for 5 years). | ||
==CT Scan== | ==CT Scan== | ||
*Melanoma can appear as a soft tissue mass on CT scan.<ref name="pmid25032021">{{cite journal |vauthors=Brant JM |title=Breathlessness with pulmonary metastases: a multimodal approach |journal=J Adv Pract Oncol |volume=4 |issue=6 |pages=415–22 |date=November 2013 |pmid=25032021 |doi= |url=}}</ref> | *Melanoma can appear as a [[soft tissue]] [[mass]] on [[Computed tomography|CT scan]].<ref name="pmid25032021">{{cite journal |vauthors=Brant JM |title=Breathlessness with pulmonary metastases: a multimodal approach |journal=J Adv Pract Oncol |volume=4 |issue=6 |pages=415–22 |date=November 2013 |pmid=25032021 |doi= |url=}}</ref> | ||
*Chest CT scan of patients with pulmonary metastatic lesions can demonstrate enlarged mediastinal adenopathy.<ref name="pmid28029320">{{cite journal |vauthors=Powell CA |title=Pulmonary Infiltrates in a Patient With Advanced Melanoma |journal=J. Clin. Oncol. |volume=35 |issue=7 |pages=705–708 |date=March 2017 |pmid=28029320 |doi=10.1200/JCO.2016.69.9793 |url=}}</ref> | *[[Chest]] [[Computed tomography|CT scan]] of [[Patient|patients]] with [[Lung|pulmonary]] [[Metastasis|metastatic]] [[Lesion|lesions]] can demonstrate enlarged [[Mediastinum|mediastinal]] [[Lymphadenopathy|adenopathy]].<ref name="pmid28029320">{{cite journal |vauthors=Powell CA |title=Pulmonary Infiltrates in a Patient With Advanced Melanoma |journal=J. Clin. Oncol. |volume=35 |issue=7 |pages=705–708 |date=March 2017 |pmid=28029320 |doi=10.1200/JCO.2016.69.9793 |url=}}</ref> | ||
*CT scan along with other modalities can also be useful for the staging of the disease, therapy assessment, and prognosis determination.<ref name="pmid26204273">{{cite journal |vauthors=Perng P, Marcus C, Subramaniam RM |title=(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis |journal=AJR Am J Roentgenol |volume=205 |issue=2 |pages=259–70 |date=August 2015 |pmid=26204273 |doi=10.2214/AJR.14.13575 |url=}}</ref> | *[[Computed tomography|CT scan]] along with other modalities can also be useful for the [[Cancer staging|staging]] of the [[disease]], therapy assessment, and [[prognosis]] determination.<ref name="pmid26204273">{{cite journal |vauthors=Perng P, Marcus C, Subramaniam RM |title=(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis |journal=AJR Am J Roentgenol |volume=205 |issue=2 |pages=259–70 |date=August 2015 |pmid=26204273 |doi=10.2214/AJR.14.13575 |url=}}</ref> | ||
*Chest CT scan is the preferred choice of chest imaging modality and is recommended for the diagnosis of metastatic lesions in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | *[[Chest]] [[Computed tomography|CT scan]] is the preferred choice of [[chest]] [[imaging]] modality and is recommended for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
:*In patients with stage IA-IV melanoma<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | :*In [[Patient|patients]] with [[Cancer staging|stage]] IA-IV melanoma<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
:*For secondary prevention of melanoma in patients who were previously diagnosed with | :*For [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IIB-IV melanoma (annually for 5 years)<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
==References== | ==References== |
Latest revision as of 18:08, 4 January 2019
Melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Melanoma CT On the Web |
American Roentgen Ray Society Images of Melanoma CT |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
Melanoma can appear as a soft tissue mass on CT scan. Chest CT scan is recommended for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).
CT Scan
- Melanoma can appear as a soft tissue mass on CT scan.[1]
- Chest CT scan of patients with pulmonary metastatic lesions can demonstrate enlarged mediastinal adenopathy.[2]
- CT scan along with other modalities can also be useful for the staging of the disease, therapy assessment, and prognosis determination.[3]
- Chest CT scan is the preferred choice of chest imaging modality and is recommended for the diagnosis of metastatic lesions in the following conditions:[4]
References
- ↑ Brant JM (November 2013). "Breathlessness with pulmonary metastases: a multimodal approach". J Adv Pract Oncol. 4 (6): 415–22. PMID 25032021.
- ↑ Powell CA (March 2017). "Pulmonary Infiltrates in a Patient With Advanced Melanoma". J. Clin. Oncol. 35 (7): 705–708. doi:10.1200/JCO.2016.69.9793. PMID 28029320.
- ↑ Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.
- ↑ 4.0 4.1 4.2 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.